Publications

2019

• Impact of 2016-WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib.
  Palandri F, Palumbo GA, Abruzzese E, Iurlo A, Polverelli N, Elli E, Bonifacio M, Bergamaschi M, Martino B, Tiribelli M, Benevolo G, Tieghi A, Sgherza N, Isidori A, Binotto G, Crugnola M, Heidel F, Cavazzini F, Bosi C, Auteri G, Cattaneo D, Foà R, Lemoli RM, Cuneo A, Krampera M, Bartoletti D, Cavo M, Vianelli N, Breccia M, Latagliata R
  Hematol Oncol 2019, 37(4), 418-23
  
• Plasma VCAM1 levels correlate with disease severity in Parkinson's disease.
  Perner C, Perner F, Gaur N, Zimmermann S, Witte OW, Heidel FH, Grosskreutz J, Prell T
  J Neuroinflammation 2019, 16(1), 94
  
• Roles of JAK2 in Aging, Inflammation, Hematopoiesis and Malignant Transformation.
  Perner F, Perner C, Ernst T, Heidel FH
  Cells 2019, 8(8)
  
• Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients.
  Polverelli N, Palumbo GA, Binotto G, Abruzzese E, Benevolo G, Bergamaschi M, Tieghi A, Bonifacio M, Breccia M, Catani L, Tiribelli M, D'Adda M, Sgherza N, Isidori A, Cavazzini F, Martino B, Latagliata R, Crugnola M, Heidel F, Bosi C, Ibatici A, Soci F, Penna D, Scaffidi L, Aversa F, Lemoli RM, Vitolo U, Cuneo A, Russo D, Cavo M, Vianelli N, Palandri F
  Hematol Oncol 2019 (epub ahead of print)
  
• Spatiotemporal Resolution of SCF Supply in Early Hematopoiesis.
  Waskow C
  Cell Stem Cell 2019, 24(3), 349-50
  

2018

• SETD1A protects HSCs from activation-induced functional decline in vivo.
  Arndt K, Kranz A, Fohgrub J, Jolly A, Bledau AS, Di Virgilio M, Lesche M, Dahl A, Höfer T, Stewart AF, Waskow C
  Blood 2018, 131(12), 1311-24
  
• Analysis of lncRNA-Protein Interactions by RNA-Protein Pull-Down Assays and RNA Immunoprecipitation (RIP).
  Bierhoff H
  Methods Mol Biol 2018, 1686, 241-50
  
• Diverging impact of cell fate determinants Scrib and Llgl1 on adhesion and migration of hematopoietic stem cells.
  Dash BP, Schnöder TM, Kathner C, Mohr J, Weinert S, Herzog C, Godavarthy PS, Zanetti C, Perner F, Braun-Dullaeus R, Hartleben B, Huber TB, Walz G, Naumann M, Ellis S, Vasioukhin V, Kähne T, Krause DS, Heidel FH
  J Cancer Res Clin Oncol 2018, 144(10), 1933-44
  
• JAK2-V617F promotes venous thrombosis through β1/β2 integrin activation.
  Edelmann B, Gupta N, Schnoeder TM, Oelschlegel AM, Shahzad K, Goldschmidt J, Philipsen L, Weinert S, Ghosh A, Saalfeld FC, Nimmagadda SC, Müller P, Braun-Dullaeus R, Mohr J, Wolleschak D, Kliche S, Amthauer H, Heidel FH, Schraven B, Isermann B, Müller AJ, Fischer T
  J Clin Invest 2018, 128(10), 4359-71
  
• Epigenetic aging of human hematopoietic cells is not accelerated upon transplantation into mice.
  Frobel J, Rahmig S, Franzen J, Waskow C, Wagner W
  Clin Epigenetics 2018, 10, 67 published during change of institution